PEDIATRIC GUILLAIN-BARRÉ SYNDROME IN MÉXICO CLINICAL FEATURES BEFORE AND DURING SARS-COV-2 PANDEMIC
DOI:
https://doi.org/10.31157/an.v29i2.625Keywords:
Guillain-Barré-Syndrome; pediatric; immunoglobulin; SARS-CoV-2; pandemic;Abstract
Introduction: Guillain-Barré Syndrome is the most common cause of acute flaccid paralysis in childhood. It is a post infectious disease immune-mediated with a rapidly progressive course, usually without relapse. The main features are progressive weakness of more than one limb, areflexia or hyporeflexia, which gets progressively worst over days-to-weeks, to potentially life-threatening severity requiring mechanical ventilation.
Objective: We aimed to describe the clinical features of pediatric Guillain-Barré Syndrome in México before and during SARS-CoV-2 pandemic.
Methods: We performed an ambispective, observational, cross-sectional study in a Mexican reference hospital from January 2013 to December 2021. Data were obtained through records: demographic, clinical, laboratories, neurophysiological variants and treatment.
Results: Here we show that of the 96 patients, 55 were males with mean age of 9 years, 72% had history of infection; progressive weakness was present in 97%, areflexia/hyporeflexia 97%, progression of symptoms 99%, mean cells of 9/mm3 and mean proteins 88 mg/dL. Admission to Pediatric Intensive Care Unit was 20%. Acute Motor Axonal Neuropathy was the most frequent subtype. Nineteen patients required mechanical ventilation. Immunoglobulin was administered in 88%. Most frequent Disability Score at discharge was bedridden/wheelchair-bound. During 2020-2021 we found two SARS-CoV-2 cases and one associated with BNT162b2 vaccine.
Conclusions: Our results demonstrate that clinical features of pediatric Guillain-Barré Syndrome are similar before and during SARS-CoV-2 pandemic, nevertheless the number of cases associated with SARS-CoV-2 infection did not find increase.
References
Guillain G BJSA. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquide cephalorachidien sans reaction cellulaire. Remarques sur les caracteres cliniques et graphiques desrefl exes tendineux. Bull Soc Med Hop Paris 1916;28:1462–70.
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. The Lancet 2016;388:717–27. https://doi.org/10.1016/S0140-6736(16)00339-1. DOI: https://doi.org/10.1016/S0140-6736(16)00339-1
Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics 2007;38:10–7. https://doi.org/10.1055/S-2007-981686. DOI: https://doi.org/10.1055/s-2007-981686
Durán RA, Fonseca-Chon I, Sotelo-Cruz N. Guillain-Barré syndrome. Experience with 91 Children at a Pediatric Hospital in Northwestern Mexico. Arch Neurocien 2016:21(1):7-16. https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=68277 (accessed May 19, 2022). DOI: https://doi.org/10.31157/an.v21i1.106
WHO. Coronavirus disease 2019 (2019-nCOV) Situation Report – 11. World Health Organization 2020:1–7.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683–90. https://doi.org/10.1001/JAMANEUROL.2020.1127. DOI: https://doi.org/10.1001/jamaneurol.2020.1127
Ray STJ, Abdel-Mannan O, Sa M, Fuller C, Wood GK, Pysden K, et al. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc Health 2021;5:631–41. https://doi.org/10.1016/S2352-4642(21)00193-0. DOI: https://doi.org/10.1016/S2352-4642(21)00193-0
IMSS. El Hospital General del CMN La Raza conmemora 67 años de su inauguración simbólica. IMSS 2019. http://www.imss.gob.mx/prensa/archivo/201910/423 (accessed August 17, 2023).
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27 Suppl:S21–4. https://doi.org/10.1002/ANA.410270707. DOI: https://doi.org/10.1002/ana.410270707
Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2:750–3. https://doi.org/10.1016/S0140-6736(78)92644-2. DOI: https://doi.org/10.1016/S0140-6736(78)92644-2
Job KM, Gamalo M, Ward RM. Pediatric Age Groups and Approach to Studies. Ther Innov Regul Sci 2019;53:584–9. https://doi.org/10.1177/2168479019856572. DOI: https://doi.org/10.1177/2168479019856572
Nachamkin I, Barbosa PA, Ung H, Lobato C, Rivera AG, Rodriguez P, et al. Patterns of Guillain-Barré syndrome in children: Results from a Mexican population. Neurology 2007;69:1665–71. https://doi.org/10.1212/01.wnl.0000265396.87983.bd. DOI: https://doi.org/10.1212/01.wnl.0000265396.87983.bd
González-Rivera, Chico-Aldama, Arzate-Barbosa, Mario R-P, Cecilia L, Irving N, Viveros Wendy DD, et al. Epidemiología del síndrome de Guillain-Barré asociado a Campylobacter jejuni en el INP. Acta Pediatr Mex 2006;27:300–3.
Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N Engl J Med 1981;304:1557–61. https://doi.org/10.1056/NEJM198106253042601. DOI: https://doi.org/10.1056/NEJM198106253042601
Grave C, Boucheron P, Rudant J, Mikaeloff Y, Tubert-Bitter P, Escolano S, et al. Seasonal influenza vaccine and Guillain-Barré syndrome: A self-controlled case series study. Neurology 2020;94:e2168–79. https://doi.org/10.1212/WNL.0000000000009180. DOI: https://doi.org/10.1212/WNL.0000000000009180
Kinnunen E, Junttila O, Haukka J, Hovi T. Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barré Syndrome. Am J Epidemiol 1998;147:69–73. https://doi.org/10.1093/OXFORDJOURNALS.AJE.A009369. DOI: https://doi.org/10.1093/oxfordjournals.aje.a009369
Nasiri J, Ghazavi M, Yaghini O, Chaldavi M. Clinical Features and Outcome of Guillain-Barré Syndrome in Children. Iran J Child Neurol 2018;12:49–57. https://doi.org/10.22037/ijcn.v12i2.15159.
Ramos-Alvarez M, Bessudo L, Sabin AB. Paralytic Syndromes Associated With Noninflammatory Cytoplasmic or Nuclear Neuronopathy: Acute Paralytic Disease in Mexican Children, Neuropathologically Distinguishable From Landry-Guillain-Barré Syndrome. JAMA 1969;207:1481–92. https://doi.org/10.1001/JAMA.1969.03150210065008. DOI: https://doi.org/10.1001/jama.207.8.1481
Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 2020;19:383–4. https://doi.org/10.1016/S1474-4422(20)30109-5. DOI: https://doi.org/10.1016/S1474-4422(20)30109-5
Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nature Medicine 2022 2022:1–10. https://doi.org/10.1038/s41591-022-02001-z. DOI: https://doi.org/10.21203/rs.3.rs-1473735/v1
Frank CHM, Almeida TVR, Marques EA, De Sousa Monteiro Q, Feitoza PVS, Borba MGS, et al. Guillain-Barré Syndrome Associated with SARS-CoV-2 Infection in a Pediatric Patient. J Trop Pediatr 2021;67. https://doi.org/10.1093/TROPEJ/FMAA044. DOI: https://doi.org/10.1093/tropej/fmaa044
Luijten LWG, Leonhard SE, van der Eijk AA, Doets AY, Appeltshauser L, Arends S, et al. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain 2021;144:3392–404. https://doi.org/10.1093/BRAIN/AWAB279. DOI: https://doi.org/10.1093/brain/awab279
López-Hernández JC, Pérez-Valdez EY, León-Manríquez E, Bazán-Rodríguez L, Galnares-Olalde JA, Jorge-De Saráchaga A, et al. Guillain-Barre syndrome during COVID-19 pandemic: experience from a referral healthcare center in Mexico. Rev Neurol 2021;73:315–20. https://doi.org/10.33588/RN.7309.2021364. DOI: https://doi.org/10.33588/rn.7309.2021364
García-Grimshaw M, Michel-Chávez A, Vera-Zertuche JM, Galnares-Olalde JA, Hernández-Vanegas LE, Figueroa-Cucurachi M, et al. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. Clin Immunol 2021;230. https://doi.org/10.1016/J.CLIM.2021.108818. DOI: https://doi.org/10.1016/j.clim.2021.108818
Malamud E, Otallah SI, Caress JB, Lapid DJ. “Guillain-Barré Syndrome After COVID-19 Vaccination in an Adolescent” [Pediatric Neurology, Volume 126, January 2022, Pages 9-10]. Pediatr Neurol 2022;128:77. https://doi.org/10.1016/J.PEDIATRNEUROL.2021.11.001. DOI: https://doi.org/10.1016/j.pediatrneurol.2021.11.001
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
September 2022-present © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.
January-September 2022 © The authors. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.
January 2014-December 2021 © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
